CLINICAL_TRIALS
trial_result
· 2025-07-04
Clinical Trial Update: AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) [Phase 2]
Summary
A Phase 2 clinical trial (JACKPOT26) evaluating AZD4205 in Peripheral T-cell Lymphoma after first-line therapy has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dizal Pharmaceuticals | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: COMPLETED